Rakuten Medical vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Rakuten Medical is a biotech developing photoimmunotherapy cancer treatment using its Illuminox platform (cetuximab sarotalocan), approved in Japan for head and neck cancer and in clinical trials globally; listed on Tokyo Stock Exchange (TYO: 4707);
About
Rakuten Medical, Inc. is a biotechnology company founded by Yoshihiro Seto in 2006 (as Aspyrian Therapeutics, renamed Rakuten Medical after acquisition by Rakuten Group) and headquartered in San Diego, California, with primary R&D and commercial operations in Japan. The company is focused on developing cancer treatments using its proprietary photoimmunotherapy (PIT) platform, branded as Illuminox. Photoimmunotherapy combines a targeted antibody conjugated to a photoabsorber dye that, when activated by near-infrared light, selectively destroys cancer cells in the illuminated region while minimizing damage to surrounding healthy tissue — a precision oncology approach distinct from traditional chemotherapy or immunotherapy.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Rakuten Medical vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.